Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Panel Favors Medtronic’s Bryan Cervical Disc Despite Durability Question

This article was originally published in The Gray Sheet

Executive Summary

FDA's Orthopedic and Rehabilitation Devices Panel overwhelmingly supported approval of Medtronic Sofamor Danek's Bryan artificial cervical spinal disc, while acknowledging that the device's long-term durability is unknown

You may also be interested in...



Medtronic To Launch Bryan Cervical Disc In July

Medtronic will begin a controlled market release of its Bryan artificial cervical disc in July, the firm announced June 11. The device was approved by FDA May 12

Medtronic To Launch Bryan Cervical Disc In July

Medtronic will begin a controlled market release of its Bryan artificial cervical disc in July, the firm announced June 11. The device was approved by FDA May 12

Research In Brief

CT angiography: Computerized tomographic angiography (CTA) is a safe and effective diagnostic method for ruling out serious cardiovascular disease in patients who come to an emergency department with chest pains, according to the lead author of a long-term study of CTA screening presented May 15 at the Society for Academic Emergency Medicine's annual conference in New Orleans. In the study, led by Judd Hollander, University of Pennsylvania, 481 patients who had no evidence of coronary blockage in a CTA scan were followed for one year. None of the patients had a heart attack or required a coronary revascularization procedure during the follow-up, although 11% were rehospitalized for further cardiac testing. "The ability to rapidly determine that there is nothing seriously wrong allows us to provide reassurance to the patient and to help reduce crowding in the emergency department," Hollander said. According to the Medical Imaging & Technology Alliance, previous research has shown that CTA screening saves $2,500 per patient versus admitting the patient to the hospital for more extensive testing. In a MITA press release, Hollander says: "The evidence now clearly shows that when used in appropriate patients in the emergency department, we can safely and rapidly reduce hospital admission and save money.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025049

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel